Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia.
- DOI
- 10.1016/j.drudis.2022.05.015
- Published
- 2022-05-18
- Container
- Drug Discov Today
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.drudis.2022.05.015,
title = {Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia.},
author = {Micallef B and Nistico R and Bjerrum OW and Sarac SB and Butler D and Serracino-Inglott A and Borg JJ.},
year = {2022},
journal = {Drug Discov Today},
doi = {10.1016/j.drudis.2022.05.015},
url = {https://doi.org/10.1016/j.drudis.2022.05.015}
}RIS
TY - JOUR TI - Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia. AU - Micallef B AU - Nistico R AU - Bjerrum OW AU - Sarac SB AU - Butler D AU - Serracino-Inglott A AU - Borg JJ. PY - 2022 JO - Drug Discov Today DO - 10.1016/j.drudis.2022.05.015 UR - https://doi.org/10.1016/j.drudis.2022.05.015 ER -
APA
B, M., R, N., OW, B., SB, S., D, B., A, S., & JJ., B. (2022). Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia.. Drug Discov Today. https://doi.org/10.1016/j.drudis.2022.05.015
Source records
- europe-pmc · retrieved 2026-09-26T03:09:51.272Z